3Lindor KD, Kowdley KV, Heatheote EJ. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 2004, 39 (3): 770-778.
4Brunt EM, Janney CC, Di Bisceglie AM, et al. Nonalcoholic steato-hepatitis: a proposal for grading and staging the histological lesion. AmJ Gastroenterol, 1999, 94:2467-2474
5Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with Salicylates or targeted disruptiln of Iklβ. Science, 2001, 293:1673-1677.
6Solga SF, Diehl AM. Non-alooholic fatty liver disease: -lumen-liver interactions and possible role for probiotics. Jouma of Hepatology,2003, 38:681-687.
7Chalasani N. Statins and hepatotoxieity: focus on patients with fatty liver. Hepatology, 2005, 41 (4): 690-695.
8DAY CP.Natural history of NAFLD:remarkably benign in the absence of cirrhosis[J].Gastroenterology,2005,129:375.
9SAITO T,MISAWA K,KAWATA S.Fatty liver and non-alcoholic steatohepatitis[J].Intern Med,2007,46(2):101.
10ICHIKAWA T,YANAGI K,MOTOYOSHI Y,et al.Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis[J].J Gastroenterol Hepatol,2006,21(12):1865.
